Evidence reviewed through September 3, 2026.
In May 2026, an international consensus renamed polycystic ovary syndrome (PCOS) polyendocrine metabolic ovarian syndrome (PMOS). The transition will take time, and most research discussed below uses the older name, so this article uses “PCOS” when describing those studies.1
Inositol is widely promoted for insulin resistance, irregular cycles, unwanted hair growth, weight, ovulation, and fertility. The evidence does not support one sweeping verdict. Some trials report improvements in laboratory measurements, but evidence for the outcomes people are more likely to feel or value remains uncertain.
The short answer
- Inositol may improve selected insulin-related laboratory markers, but key pooled estimates in the guideline-linked review came from small studies and very-low-certainty evidence.
- Reliable benefits have not been established for weight, hirsutism, regular cycles, ovulation, clinical pregnancy, or live birth.
- No inositol type, dose, combination, or myo-inositol-to-D-chiro-inositol ratio has been proven best.
- The international guideline allows inositol to be considered according to personal preferences and values, but regards it as experimental for PCOS-related infertility.23
What the strongest evidence says
| Evidence source | What it included | Most defensible conclusion |
|---|---|---|
| 2024 guideline-linked systematic review | 30 randomized trials; 2,230 participants | Possible metabolic signals, but evidence was mostly low or very low certainty.2 |
| 2023 international guideline | Evidence plus multidisciplinary and lived-experience input | Inositol may be considered, but clinical benefits are limited and no specific formulation can be recommended.3 |
| 2025 pregnancy trial | 464 pregnant participants with PCOS | Four grams of myo-inositol daily did not reduce a composite of gestational diabetes, preeclampsia, or preterm birth.4 |
| 2026 umbrella review | 13 prior meta-analyses; 85 evidence items | Favorable signals were reported, but none was high certainty; trial overlap was not formally assessed, creating possible duplicate bias.5 |
Laboratory markers are not the same as clinical outcomes
The 2024 systematic review is the best starting point because it was performed for the international PCOS guideline. Researchers screened 43 otherwise eligible trials for research-integrity concerns and included 30; 19 could contribute to a meta-analysis. Most trials were small, short, and at risk of bias.2
The integrity picture has changed since that review was published. Two included fertility-treatment trials were retracted in 2025–2026,1113 and another received an expression of concern over a possible undisclosed conflict of interest.12 This does not invalidate every pooled estimate, but it makes fertility and formulation-specific conclusions still less secure.
For myo-inositol plus folic acid versus folic acid alone, pooled results favored inositol for fasting insulin (mean difference −4.17 μU/mL; 95% CI, −5.14 to −3.20) and HOMA-IR (−1.24; 95% CI, −1.50 to −0.99). However, each estimate came from only two trials totaling 70 participants and was rated very low certainty. These are surrogate laboratory markers; they do not prove that symptoms, long-term health, or fertility improve.
The apparently large ovulation effect for D-chiro-inositol versus placebo came from two trials totaling just 64 participants (odds ratio 11.50; 95% CI, 3.40 to 38.91). The very wide interval shows substantial uncertainty. Those trials used 600–1,200 mg of D-chiro-inositol daily, so their result cannot be transferred to products containing much smaller amounts.
When myo-inositol was compared with metformin, pooled estimates did not show clear differences for regular menstruation (OR 1.85; 95% CI, 0.68 to 5.01), ovulation (OR 1.28; 95% CI, 0.59 to 2.77), or clinical pregnancy (OR 1.18; 95% CI, 0.79 to 1.78). Low-certainty evidence favored metformin for hirsutism and waist-to-hip ratio. Myo-inositol appeared to cause fewer gastrointestinal effects, but 23 of 29 trial reports did not report adverse events, so tolerability is not as well characterized as the headline suggests.2
How the guideline translates that evidence
The 2023 International Evidence-based Guideline says inositol in any form could be considered based on an individual’s preferences and values. It notes limited apparent harm and possible improvement in some metabolic measures, alongside limited clinical benefit for ovulation, hirsutism, or weight.
It also states that no specific type, dose, ratio, or combination can be recommended because quality evidence is lacking. For PCOS-related infertility, it calls inositol experimental because effects on ovulation, clinical pregnancy, live birth, and safety remain too uncertain.3
What newer studies add
The most informative new randomized trial addressed a narrow pregnancy question. In 13 Dutch hospitals, 464 pregnant participants with PCOS received either 2 g of myo-inositol twice daily or placebo, with folic acid in both groups. The composite outcome of gestational diabetes, preeclampsia, or preterm birth occurred in 25.0% versus 26.8% (risk ratio 0.93; 95% CI, 0.68 to 1.28). That is not evidence of benefit for preventing those complications. It also does not answer whether inositol affects preconception cycles or fertility.4
A 2026 umbrella review reported favorable signals across several metabolic and reproductive outcomes. But it summarized 13 earlier meta-analyses rather than new, independent participant groups; overlap among the original trials was not quantified. None of its 85 evidence items was high certainty: 18.9% were moderate, 40.0% low, and 41.1% very low certainty. We view it as hypothesis-supporting context, not evidence that supersedes the international guideline.5
Is the 40:1 ratio proven best?
No. The direct study most often used to support 40:1 assigned 56 participants across seven inositol ratios—only eight people per group—for three months. It was open-label and had no placebo group.6 That is far too little evidence to establish an optimal ratio, and the international guideline explicitly declines to recommend one.3
A ratio can accurately describe a formula without proving that the formula is superior or clinically effective.
What about alpha-lactalbumin?
Alpha-lactalbumin is a milk-derived protein studied alongside myo-inositol. A 2018 fixed-sequence experiment in 18 healthy adults reported higher myo-inositol blood exposure after a single 6 g dose taken with 150 mg of 96%-pure alpha-lactalbumin than after myo-inositol alone. Everyone received the treatments in the same order; the study did not enroll people with PCOS or measure symptoms, cycles, ovulation, or fertility.7
Two small PCOS studies reported encouraging signals after adding alpha-lactalbumin, but their open-label designs, small samples, selected participants, attrition, and industry involvement prevent firm conclusions.89 They do not establish a validated condition called “inositol resistance” or show that alpha-lactalbumin improves clinical outcomes.
A separate 2021 multicenter paper was formally retracted in June 2026 after unresolved ethics, methodological, statistical, reliability, and conflict-of-interest concerns. WrenLife gives that paper zero evidentiary weight.10
Why we updated this article
Earlier WrenLife coverage used the phrase “inositol-resistant PCOS” and gave too much weight to preliminary alpha-lactalbumin research. The evidence does not justify treating that phrase as an established clinical category, and one previously cited study has now been retracted. Updating public-facing conclusions when the evidence changes is part of responsible science communication.
Practical questions to discuss with a clinician
Before trying inositol, consider asking:
- Which specific symptom, measurement, or goal are we trying to change?
- Could it affect my diabetes medication, fertility treatment, or other care?
- How and when will we judge whether it is helping?
- When should I stop—particularly if I become pregnant?
The takeaway
Inositol is biologically plausible and reasonably well studied for a supplement, but the evidence is less certain than many marketing claims suggest. Some insulin-related laboratory measures may improve. We still cannot reliably predict benefits for weight, unwanted hair growth, cycles, ovulation, pregnancy, or live birth, and no dose or ratio has been proven best.
Inositol may be one option in a shared decision—not a cure or a substitute for individualized care.
Scientific references
1. Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026. doi:10.1016/S0140-6736(26)00717-8.
2. Fitz V, Graca S, Mahalingaiah S, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024;109(6):1630–1655. doi:10.1210/clinem/dgad762.
3. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463.
4. van der Wel AWT, Frank CMC, Bout-Rebel R, et al. Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. JAMA. 2025;334(13):1151–1159. doi:10.1001/jama.2025.13668.
5. Duan M, Yang M, Li C, et al. Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. Front Endocrinol. 2026;17:1741509. doi:10.3389/fendo.2026.1741509.
6. Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512–5521. doi:10.26355/eurrev_201906_18223.
7. Monastra G, Sambuy Y, Ferruzza S, Ferrari D, Ranaldi G. Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro. Curr Drug Deliv. 2018;15(9):1305–1311. doi:10.2174/1567201815666180509102641.
8. Montanino Oliva M, Buonomo G, Calcagno M, Unfer V. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J Ovarian Res. 2018;11:38. doi:10.1186/s13048-018-0411-2.
9. Kamenov Z, Gateva A, Dinicola S, Unfer V. Comparing the Efficacy of Myo-Inositol Plus Alpha-Lactalbumin vs. Myo-Inositol Alone on Reproductive and Metabolic Disturbances of Polycystic Ovary Syndrome. Metabolites. 2023;13(6):717. doi:10.3390/metabo13060717.
10. Retraction Note: A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients. Eur Rev Med Pharmacol Sci. Published June 30, 2026. doi:10.26355/eurrev_202606_37853.
11. Retraction notice to “Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles”. Fertil Steril. 2025;123(3):550. doi:10.1016/j.fertnstert.2025.01.028.
12. Expression of Concern: “Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles”. Eur Rev Med Pharmacol Sci. 2025;29(7):348. doi:10.26355/eurrev_202507_37339.
13. Statement of retraction: “Effect of myo-inositol and melatonin versus myo-inositol … for improving in vitro fertilization”. Gynecol Endocrinol. Published February 2, 2026. doi:10.1080/09513590.2026.2625568.
This article is for education only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent disease. Discuss individual needs, medication interactions, fertility treatment, and pregnancy with a qualified healthcare professional.
